JCAR024
Drug
Celgene Corporation
Total Payments
$1.2M
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.2M | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells engineered to express a ROR1?specific chimeric antigen receptor. (JCAR024 ROR-1)-BCM) | Celgene Corporation | $1.2M | 0 |
Top Doctors Receiving Payments for JCAR024
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $1.2M | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $1.2M
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 0
- Transactions 1
About JCAR024
JCAR024 is a drug associated with $1.2M in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $1.2M was paid across 1 transactions to 0 doctors.
The most common payment nature for JCAR024 is "Unspecified" ($1.2M, 100.0% of total).
JCAR024 is associated with 1 research study, including "Phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells engineered to express a ROR1?specific chimeric antigen receptor. (JCAR024 ROR-1)-BCM)" ($1.2M).